DYN — Dyne Therapeutics, Inc. Stock Price, Chart & AI Report

Positive Feb 22, 2026 • 21:00 UTC GlobeNewswire Inc. • Na

Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference

Dyne Therapeutics will present five presentations at the 2026 MDA Clinical & Scientific Conference, including new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD and Phase 3 trial design for z-basivarsen in DM1. The presentations demonstrate the strength of Dyne's FORCE platform across three neuromuscular diseases.

DYN Dyne Therapeutics DMD myotonic dystrophy Pompe disease z-rostudirsen z-basivarsen DELIVER trial

Sentiment note

Company announced positive clinical trial results with new cardiopulmonary function data from DELIVER trial, multiple oral presentations at major conference, and expansion of pipeline across three neuromuscular diseases. The FORCE platform is described as having potential to be 'best-in-class' with demonstrated breadth and durability of functional improvement.

Neutral Dec 10, 2025 • 02:42 UTC GlobeNewswire Inc. • Dyne Therapeutics

Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock

Dyne Therapeutics plans to raise $350 million through a public offering of 18,980,478 common stock shares at $18.44 per share, with potential additional shares through underwriter option.

DYN MS MSPA MSPE public offering stock sale financing neuromuscular diseases

Sentiment note

The company is raising capital through a standard public stock offering, which indicates a strategic financial move to fund ongoing research and development without immediate positive or negative implications

Negative Dec 9, 2025 • 21:34 UTC The Motley Fool • Dan Caplinger

Biggest Market Movers Today, Dec. 9: WRBY, DYN, & More

Stock markets remained relatively stable on Tuesday, awaiting the Federal Reserve's interest rate decision. Notable movements included gains for Warby Parker on AI prospects and Pan American Silver due to rising silver prices, while Dyne Therapeutics and SLM experienced stock price declines.

WRBY PAAS DYN SLM stock market Federal Reserve interest rates AI

Sentiment note

Stock dropped 17% after announcing a $300 million secondary stock offering, raising dilution concerns

Positive Oct 27, 2025 • 22:17 UTC The Motley Fool • Eric Volkman

Why Dyne Therapeutics Stock Crushed the Market on Monday

Dyne Therapeutics stock surged over 41% after Novartis announced a $12 billion acquisition of Avidity Biosciences, a peer biotech company developing similar muscle disorder therapies using antibody-based treatments.

DYN RNA NVS biotech acquisition muscle disorders antibody therapy

Sentiment note

Stock price increased significantly due to market speculation about potential future acquisition based on similar company's premium buyout

Positive Sep 29, 2025 • 12:35 UTC Benzinga • Globe Newswire

Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy

Dyne Therapeutics received Orphan Drug designation in Japan for DYNE-251, a potential treatment for Duchenne muscular dystrophy. The drug has shown sustained functional improvement in clinical trials and has received multiple regulatory designations across different regions.

DYN Orphan Drug designation Duchenne muscular dystrophy DYNE-251 clinical trials neuromuscular disease

Sentiment note

Company received important regulatory designation in Japan, demonstrated promising clinical trial results, and continues to advance its therapeutic development for a rare disease with significant unmet medical needs

Positive Aug 28, 2025 • 17:00 UTC GlobeNewswire Inc. • Delveinsight

Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight

Antisense oligonucleotide (ASO) therapeutics are emerging as a promising treatment approach for rare genetic and neuromuscular disorders, with over 70 pharmaceutical companies actively developing 90+ pipeline therapeutics targeting specific genetic mechanisms.

NVS BIIB IONS DYN antisense oligonucleotides gene therapy clinical trials genetic medicine

Sentiment note

Received FDA Fast Track designation for DYNE-101 in myotonic dystrophy type 1 treatment

Negative Aug 17, 2025 • 16:42 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

Dyne Therapeutics announced a delay in FDA approval for DYNE-101, an experimental therapy for myotonic dystrophy type 1, pushing enrollment and potential submission timelines later into 2025 and 2026.

DYN FDA drug approval clinical trials securities investigation

Sentiment note

Stock price dropped 21.42% due to delayed FDA approval timeline, indicating investor concern about potential setbacks in drug development and regulatory process

Negative Aug 9, 2025 • 16:38 UTC GlobeNewswire Inc. • Danielle Peyton

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

Pomerantz LLP is investigating potential securities fraud at Dyne Therapeutics after the company delayed FDA approval for DYNE-101, an experimental therapy for myotonic dystrophy type 1, causing its stock price to drop 21.42%.

DYN securities fraud FDA approval clinical trials stock price drop

Sentiment note

Stock price fell 21.42% due to delayed FDA approval timeline, potential regulatory challenges, and ongoing legal investigation suggesting potential corporate misconduct

Negative Jul 14, 2025 • 14:00 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

Dyne Therapeutics announced a delay in FDA approval for DYNE-101, an experimental therapy for myotonic dystrophy type 1, pushing back enrollment and potential submission timelines. The stock price dropped 21.42% following the announcement.

DYN FDA drug approval clinical trials securities investigation

Sentiment note

Stock price dropped 21.42% due to delayed FDA approval timeline for experimental therapy, indicating investor uncertainty and potential setback in drug development

Neutral Jul 1, 2025 • 01:45 UTC GlobeNewswire Inc. • Dyne Therapeutics, Inc.

Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

Dyne Therapeutics plans to raise $200 million through a public offering of 24,242,425 common stock shares at $8.25 per share, with potential additional shares through underwriter option.

DYN MS MSPA MSPE public offering stock financing neuromuscular diseases

Sentiment note

The company is raising capital through a standard public offering, which suggests financial strategy for growth but not necessarily a strong positive or negative signal

Negative Jun 24, 2025 • 07:43 UTC Benzinga • Prnewswire

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - DYN

Dyne Therapeutics is being investigated for potential securities fraud violations related to misleading statements or failure to disclose information to investors. The investigation follows a drop in the company's stock price after it announced changes to a clinical trial protocol.

DYN Dyne Therapeutics securities fraud clinical trial

Sentiment note

The company is being investigated for potential securities fraud violations, which could negatively impact investor confidence and the stock price.

Positive Mar 16, 2025 • 23:00 UTC GlobeNewswire Inc. • N/A

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Dyne Therapeutics announced positive long-term data from its Phase 1/2 DELIVER trial of DYNE-251 in Duchenne muscular dystrophy, showing sustained functional improvement and a favorable safety profile. The company plans to submit for U.S. accelerated approval in early 2026.

DYN Dyne Therapeutics DYNE-251 Duchenne muscular dystrophy clinical trial functional improvement accelerated approval

Sentiment note

The article highlights positive long-term data from Dyne Therapeutics' DYNE-251 clinical trial, demonstrating sustained functional improvement and a favorable safety profile. The company is also making progress towards a potential accelerated approval submission, indicating a positive outlook for the company's development efforts.